---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060978"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:04:56.914866+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eloxx Q1 net loss narrows to $6.2M; cash runway into Q3 2023

## Summary
- Net loss of $6.2M ($2.88/sh) vs $11.6M ($5.36/sh) in Q1 2022; R&D and G&A expenses decreased.
- Cash and equivalents $4.9M at March 31; amended Hercules loan reduced minimum cash to $2.25M, interest-only until Sep 1, 2023.
- Current cash expected to fund operations into Q3 2023, assuming Phase 3 activities start in Q3.
- Topline data for ELX-02 in Alport syndrome (including biopsy) expected H1 2023; meaningful protein reduction seen in one patient.
- FDA cleared ZKN-013 SAD trial for RDEB; preclinical showed up to 18-fold increase in full-length COL VII protein.

## SEC filing metadata
- accession: 0001104659-23-060978
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923060978/0001104659-23-060978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923060978/tm2315845d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060978
- JSON: https://secwatch.observer/filing/0001104659-23-060978.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.